<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141072</url>
  </required_header>
  <id_info>
    <org_study_id>SPS</org_study_id>
    <nct_id>NCT04141072</nct_id>
  </id_info>
  <brief_title>Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study</brief_title>
  <official_title>Shrunken Pore Syndrome's Effect on Mortality in Elective Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Bjursten</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <brief_summary>
    <textblock>
      Renal dysfunction is considered a major risk factor in cardiac surgery. Renal function has
      earlier been estimated by creatinine and more recently by cystatin C, both of which are
      analysed in a blood sample. New evidence seems to suggest that if the ratio between estimated
      renal function from cystatin C and creatinine is below 60% the patient has a higher rate of
      mortality irrespective of renal function. This syndrome is named Shrunken Pore Syndrome.

      We study patients whom have undergone elective cardiac surgery at our institution and on whom
      we before the surgery has collected blood samples. They are all included in our in house
      patient registry and qulaity database and afterwards we match this data to our national tax
      registry to get data on mortality.

      Our aim is to evaluate whether Shrunken Pore Syndrome influence mortality following elective
      cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Actual">January 10, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 January 2010 - 1 January 2019</time_frame>
    <description>All cause mortality</description>
  </primary_outcome>
  <enrollment type="Actual">4719</enrollment>
  <condition>Shrunken Pore Syndrome</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Shrunken Pore Syndrome</intervention_name>
    <description>eGFR Cystatin C ≤ 60% of eGFR Creatinine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Skåne University Hospital in Lund is a tertiary care hospital that is the sole provider of
        cardiac surgery to the Southern part of Sweden, comprising 1 500 000 people.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective CABG and/or sAVR at the department of Cardiothoracic Surgery, Skåne
             University Hospital in Lund, Sweden between 1 January 2010 and 31 December 2015.

        Exclusion Criteria:

          -  Emergency operation

          -  Redo operation

          -  Preoperatively missing cystatin C or creatinine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Bjursten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skåne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <state>Skåne</state>
        <zip>22241</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Dardashti A, Nozohoor S, Grubb A, Bjursten H. Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. Scand J Clin Lab Invest. 2016;76(1):74-81. doi: 10.3109/00365513.2015.1099724.</citation>
    <PMID>26647957</PMID>
  </reference>
  <reference>
    <citation>Grubb A, Lindström V, Jonsson M, Bäck SE, Åhlund T, Rippe B, Christensson A. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'. Scand J Clin Lab Invest. 2015 Jul;75(4):333-40. doi: 10.3109/00365513.2015.1025427.</citation>
    <PMID>25919022</PMID>
  </reference>
  <results_reference>
    <citation>Herou E, Dardashti A, Nozohoor S, Zindovic I, Ederoth P, Grubb A, Bjursten H. The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFR(cystatin C)/eGFR(creatinine)-ratio. Scand J Clin Lab Invest. 2019 May;79(3):167-173. doi: 10.1080/00365513.2019.1576101. Epub 2019 Feb 15.</citation>
    <PMID>30767571</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Henrik Bjursten</investigator_full_name>
    <investigator_title>Assoc. Prof</investigator_title>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>Creatinine</keyword>
  <keyword>Cystatin C</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>GFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

